loader image

LATVIAN

BIOMEDICAL

RESEARCH AND STUDY CENTRE

RESEARCH AND EDUCATION IN BIOMEDICINE FROM GENES TO HUMAN

Project title: Improvement of Cardiovascular Disease Patient Diagnostics and Treatment at Pauls Stradiņš Clinical University Hospital

Funding The pilot project is being implemented within the framework of the European Union Recovery Fund project (Project No. 4.3.1.1.i.0/1/22/I/VM/001).

Project identification No.: 04

Contract No.: NVD-9/96-2024

Period: 18 months from October 3, 2024, to March 31, 2026.

Project costs: EUR 143 000,06

Principal Investigator BMC: Dr.biol. J.Kloviņš

Leading partner: State Limited Liability Company “Paula Stradiņa Clinical University Hospital”

Project summary:

Objective:
To improve the diagnosis and treatment options for cardiovascular disease patients within three specific disease groups at Paula Stradiņa Clinical University Hospital:

  1. Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Enhance diagnostics and treatment options in Latvia by providing treatment through balloon pulmonary angioplasty (BPA).
  2. Introduce genetic testing that meets international standards, ensuring fast and cost-effective diagnostics within the Lipid Clinic model. This approach aims to improve diagnosis and refine indications for early primary prevention, reducing the prevalence of early cardiovascular disease in Latvia.
  3. Critical Limb Ischemia (CLI) and Carotid Artery Stenosis (CAS): Reduce cardiovascular mortality rates among patients suffering from CLI and CAS.

Information published 05.11.2024.

Progress of the project:

5 November 2024 – 30 April 2025

A method based on third-generation sequencing technology has been developed for targeted detection of genetic variants associated with familial hypercholesterolemia risk in three genes (LDLR, APOB, PCSK9). The laboratory test with its methodological description are prepared for transfer to the staff of the Laboratory of Pauls Stradiņš Clinical University Hospital. To date, 25 hypercholesterolemia patients have been tested using this newly developed method. For patients with negative results, comprehensive whole genome sequencing is performed.

Information published 30.04.2025.